Les medicaments anti inflammatoires non steroidiens

A new report launched on 19 September finds that very few antibiotics currently in development address the serious and growing threat of antimicrobial resistance. “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” shows that most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for drug-resistant tuberculosis and 12 other classes of priority pathogens identified by WHO.

Les medicaments anti inflammatoires non steroidiens

les medicaments anti inflammatoires non steroidiens

Media:

les medicaments anti inflammatoires non steroidiensles medicaments anti inflammatoires non steroidiensles medicaments anti inflammatoires non steroidiensles medicaments anti inflammatoires non steroidiensles medicaments anti inflammatoires non steroidiens